2-methyl-2-{3-[(3S)-1-({[4-(propan-2-yl)phenyl]methoxy}carbonyl)piperidin-3-yl]phenoxy}propanoic acid

• ChemBase编号: 154735
• 分子式: C26H33NO5
• 平均质量: 439.54392
• 单一同位素质量: 439.23587316
• SMILES: CC(C)c1ccc(cc1)COC(=O)N1CCC[C@H](C1)c1cccc(c1)OC(C)(C)C(=O)O
• Canonical SMILES: O=C(N1CCC[C@H](C1)c1cccc(c1)OC(C(=O)O)(C)C)OCc1ccc(cc1)C(C)C
• InChI: InChI=1S/C26H33NO5/c1-18(2)20-12-10-19(11-13-20)17-31-25(30)27-14-6-8-22(16-27)21-7-5-9-23(15-21)32-26(3,4)24(28)29/h5,7,9-13,15,18,22H,6,8,14,16-17H2,1-4H3,(H,28,29)/t22-/m1/s1
• InChIKey: CSLFIHDRJSTULR-JOCHJYFZSA-N

名称和登记号

名称

• IUPAC标准名: 2-methyl-2-{3-[(3S)-1-({[4-(propan-2-yl)phenyl]methoxy}carbonyl)piperidin-3-yl]phenoxy}propanoic acid
• IUPAC传统名: 2-{3-[(3S)-1-{[(4-isopropylphenyl)methoxy]carbonyl}piperidin-3-yl]phenoxy}-2-methylpropanoic acid
• 别名: (S)-2-(3-(1-((4-Isopropylbenzyloxy)carbonyl)piperidin-3-yl)phenoxy)-2-methylpropanoic acid; CP-868388; N-[3-(4-Chlorophenyl)-3-[4-(2-thiazolylcarbonyl)phenoxy]propyl]-N-methylglycine Hydrochloride Hydrate; CP-802079 Hydrochloride Hydrate

登记号

• CAS号: 385436-79-3; 702681-67-2
• MDL号: MFCD18452851
• PubChem SID: 162248873
• PubChem CID: 10433320

理论计算性质

• Acid pKa: 3.8241458
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 3.997944
• LogD (pH = 7.4): 2.4256952
• Log P: 5.676822
• 摩尔折射率: 123.1499 cm^3
• 极化性: 47.979145 Å^3
• 极化表面积: 76.07 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: DMSO: ≥30 mg/mL
• 外观: white to off-white powder
• 比旋光度: [α]/D -50 to -65°, c = 0.2 in methanol

安全信息

• 欧盟危险性物质标志: 环境危害性(Nature polluting) (N); 有毒(Toxic) (T)
• 德国WGK号: 3
• 危险公开号: 25-50/53
• 安全公开号: 45-60-61
• GHS危险品标识: GHS06; GHS09
• GHS警示词: Danger
• GHS危险声明: H301-H410
• GHS警示性声明: P273-P301 + P310-P501
• 保存温度: 2-8°C

产品相关信息

• 纯度: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C26H33NO5

详细说明

Sigma Aldrich - PZ0149

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
CP-868388 is a potent PPARα agonist with a Ki of 10.8 nM.

Toronto Research Chemicals - C781390

CP-802079 is a potent and selective glycine transporter type 1 (GlyT1) antagonist. Antagonists of GlyT1 increase levels of glycine in the synaptic cleft and, like direct glycine site agonists, they can augment NMDAR currents and NMDAR-mediated functions.

参考文献

• Attwell, D., et al.: Neuron, 11, 401 (1993)
• Grabs, D., et al.: J. Biol. Chem., 272, 13419 (1993)
• Billups, D., et al.: Eur. J. Neurosci., 18, 2975 (1993)